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Background: The potential of genetic testing to rapidly diagnose drug resistance has lead to the development of
new diagnostic assays. However, prior to implementation in a given setting, the association of specific mutations
with specific drug resistance phenotypes should be evaluated. The purpose of this study was to evaluate molecular
markers in predicting drug resistance in the Central Region of Cameroon.
Results: From April 2010 and March 2011, 725 smear positive pulmonary tuberculosis patients were enrolled and all
positive cultures were tested for drug susceptibility. A total of 63 drug resistant and 100 drug sensitive
Mycobacterium tuberculosis complex clinical isolates were screened for genetic mutations in katG, inhA, ahpC, rpoB,
rpsL, rrs, gidB and embCAB loci using DNA sequencing. Of the 44 isoniazid resistant (INHR) isolates (24 high level,
1 μg/ml and 20 low level, 0.2 μg/ml), 73% (32/44) carried the katG315 and/or the −15 inhA promoter mutations. Of
the 24 high level INHR, 17 (70.8%) harbored katG315 mutation, 1 a point mutation (−15C→ T) in the inhA promoter
and 6 were (25.0%) wild types. Thus, for INHR high level detection, katG315 mutation had a specificity and a
sensitivity of 100% and 70.8% respectively. Of the 20 low level INHR, 10 (50.0%) had a −15C→ T mutation in the
inhA promoter region, and 1 (2.2%) a −32G→ A mutation in the ahpC promoter region. All of the 7 rifampicin
resistant (RIFR) isolates carried mutations in the rpoB gene (at codons Ser531Leu (71.4%), His526Asp (14.3%), and
Asp516Val (14.3%)). Of the 27 streptomycin resistant (SMR) isolates, 7 carried mutations at the rpsL and the gidB
genes. 1 of the 2 ethambutol resistant (EMBR) isolates displayed a mutation in embB gene.
Conclusion: This study provided the first molecular investigation assessing the correlation of phenotypic to genotypic
characteristics on MTB isolates from the Central Region of Cameroon using DNA sequencing. Mutations on rpoB,
katG315 and −15 point mutations in inhA promoter loci could be used as markers for RIF and INH -resistance detection
respectively.
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Despite the availability of an effective treatment for de-
cades, tuberculosis (TB) continues to cause great mortal-
ity and suffering, especially in poor and less-developed
countries. Its association with the HIV/AIDS pandemic
forms a lethal combination. In addition, multidrug resist-
ant (MDR) TB and the recently-described extensively drug
resistant (XDR) TB severely complicate the management
and control of the disease worldwide [1,2]. Almost 8.8
million new cases of TB were reported in 2010, and 1.4
million deaths were attributed to the disease. Asia and
Sub-Saharan Africa accounted for 85% of new cases of TB
worldwide [3]. Of the 8.8 million incident cases in 2010,
1.1 million (13%) were among people living with HIV.
Tuberculosis remains a common disease in Cameroon,
with an estimated of 25 000 cases annually [4]. Like in
other poor resources countries, therapeutic decisions are
most often made by algorithms according to WHO guide-
lines. Inadequate or improper prescription of drugs, poor
patient compliance and supervision of therapy may lead to
the emergence of drug resistant strains [5]. Drug resist-
ance in tuberculosis (TB) is a matter of great concern for
TB control programs since these strains could spread in
the community, stressing the need for early detection of
drug resistance and subsequently initiation of adjusted
therapy. Conventional diagnosis of drug-resistance in
MTB strains relies heavily upon mycobacterial culture and
drug susceptibility testing in liquid or solid media. Usually,
results are only obtained after weeks to months of incuba-
tion and many developing countries lack the resources to
establish the stringent laboratory conditions needed for
these growth-based methods. From a clinical perspective,
the existing growth-based diagnostics are too slow as
patients undergoing treatment with drugs to which they
are resistant, remain contagious, and those with XDR-
TB and HIV often die before they are even diagnosed
[6]. Major advances in molecular biology and the avail-
ability of new information generated after deciphering
the complete genome sequence of M. tuberculosis [7],
have led to the development of new tools for rapid de-
tection of drug resistance [8,9]. Molecular methods are
based on assigning the presence or absence of certain
mutations in specific positions or genetic locations which
are known to be associated with resistance [10]. About
95% of rifampicin (RIF) -resistant strains have mutations
in the 81-bp core region of the rpoB gene encoding the
β-subunit of the RNA polymerase, named RIF-Resistance
Determining Region (RRDR) [11]. In contrast to RIF, the
situation for isoniazid (INH) is much more complex.
Resistance mutations have been reported in at least 4
different genes including katG, inhA, ahpC and oxyR
[10]. Meanwhile, resistance against streptomycin (SM)
has been reported to be associated with mutations in rrs
gene, which codes for 16S ribosomal RNA, and rpsLcoding for the ribosomal protein S12 [12] and these mu-
tations are found in a limited proportion of clinically
isolated SM-resistant M. tuberculosis strains. Recently,
Okamoto et al. [13] found that mutations within the
gidB gene which encodes a conserved 7-methylguanosine
(m7G) methyltransferase specific for the 16S rRNA, is
associated with low-level SM-resistance and are an im-
portant cause of resistance found in 33% of resistant
M. tuberculosis isolates. Resistance to ethambutol (EMB)
is primarily mediated by mutations in the embB gene,
coding for an arabinosyltransferase participating in myco-
bacterial cell wall synthesis, with codon 306 being most
frequently affected [14]. Furthermore, mutations in the
embA [15,16] and upstream of embC [16,17] are also
involved in EMB -resistance.
Since the frequency and type of gene mutation varies
greatly among different geographic regions in the world
[18], it is important to evaluate the type and distribution
of resistance associated mutations as a prerequisite for a
large-scale implementation of genotypic approaches aimed
at rapidly detecting resistance. However, up to now data
assessing sensitivity and specificity of specific mutations
for the detection of drug resistance phenotypes in our
settings is still unavailable. Therefore CANTAM (Central
Africa Network for Tuberculosis, HIV/AIDS and Malaria)
an EDCTP (European and Developing Clinical Trials
Partnership) funded network [19], with the goal to es-
tablish a cohort and prepare new sites for conducting
future clinical trials of new TB drugs and vaccines in
Central Africa countries, carried out a population based
study, involving MTBC strains from Central region of
Cameroon, to determine the genetic basis of first line
drug resistance.Methods
Mycobacterial isolates
During this baseline study carried out between April
2010 and March 2011, 725 smear positive pulmonary
tuberculosis patients were enrolled at Jamot Hospital
and Mbalmayo District Hospital. All positive cultures
were tested for drug susceptibility to INH (0.2 μg/ml and
1 μg/ml), RIF (40 μg/ml), EMB (2 μg/ml), SM (4 μg/ml),
OFX (2 μg/ml) and KAN (20 μg/ml) by the indirect
proportion method on Lowenstein Jensen medium [20].
Phenotypically, 44 isolates were INHR (24 high level and
20 low level), 27 isolates were SMR, 7 isolates were RIFR
and 2 isolates were EMBR. The 63 resistant isolates to
INH, RIF, SM and EMB or MDR were screened for gen-
etic mutations. In addition, M. tuberculosis strain H37Rv
(susceptible) and 100 fully susceptible clinical isolates
from the panel of susceptible strains collected during the
study period were included to serve as controls. The study
was approved by the Cameroon National Ethic Committee
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informed consent was obtained from all study subjects.
DNA extraction
Briefly, a loop-full of mycobacterial colonies was sus-
pended in 400 μl of 10 mM Tris–HCl, 1 mM EDTA
(pH 7.0) buffer and inactivated at 90°C for 30 min. The
suspension was then centrifuged at 12,000 g for 1 min
and the supernatant, containing nucleic acids, was har-
vested and transferred into a new eppendorf tube. Crude
DNA extracts were stored at −20°C and then shipped to
Germany for molecular analysis according to International
Air Transport Association guidelines.
PCR amplification of target genes
The DNA extract was used as a template for PCR with
the primers listed in Table 1. Each final PCR volume of
20 μl contained 10× PCR buffer (Qiagen, Germany), 5%
DMSO, 20 pmol of forward and 20 pmol of reverse
primers, 11.9 μl of distilled water, 0.5 μl MgCl2 25 mM
(Qiagen, Germany), dNTPs at a final concentration of
500 μM, 0.2 μl of Taq polymerase 5 U/μL (Qiagen,Table 1 Primers used in the study
Loci Primers Sequences
katG F 5′-GAAACAGCGGCGCTGATCGT-3′
R 5′- GTTGTCCCATTTCGTCGGGG- 3′
fabGI-inhA F 5′-CCTCGCTGCCCAGAAAGGGA-3′
R 5′-ATCCCCCGGTTTCCTCCGGT-3′
inhA (ORF) F 5′- GAACTCGACGTGCAAAAC – 3′






R 5′- TCTAGTCTGCCCGTATCGCC −3′
rrs912 F 5′- GTAGTCCACGCCGTAAACGG −3′
R 5′- AGGCCACAAGGGAACGCCTA −3′
rpsL F 5′- GGCCGACAAACAGAACGT −3′
R 5′- GTTCACCAACTGGGTGAC −3′
embC F 5′- GTTCGACAAGCGCGCCACAC −3′
R 5′- CGGAGGTAGATGGTAGCCGG −3′
embA F 5′- GCCGGCTATGTAGCCAACTA −3′
R 5′- GACCGTTCCACCAACACC −3′
embB F 5′- CCGACCACGCTGAAACTG −3′
R 5′- GTAATACCAGCCGAAGGGATCCT −3′
gidB F 5′-CGCCGAGTCGTTGTGCT-3′
R 5′-AGCCTGGCCCGACCTTA-3′
T° = Temperature.Germany), and 2 μl of crude DNA extract (≈50 ng). The
cycling program included a cycle of an initial denaturation
step at 94°C for 5 min, followed by 35 cycles of denatur-
ation at 94°C for 1 min, annealing at the temperature and
time indicated in Table 1, and elongation at 72°C for
1 min. The final elongation step was set at 72°C for
10 min for one cycle. The PCR products were examined
by gel electrophoresis and purified by use of a Nucleospin
Extract II kit (Macherey Nagel, Germany) according to the
manufacturer instructions.
Sequencing
Purified PCR products were sequenced with the same
primers using the ABI’s Big dye terminator kit (Applied
Biosystems, USA) according to the manufacturer’s instruc-
tions. At each locus, both forward and reverse primers at
each locus were included in order to maximize the cover-
age of the amplified gene fragment, and the reproducibility
of the results. Sequencing reactions include 1 μl big dye,
2 μl sequencing buffer, 0.5 μl of each 2.5 μM primer, a
volume of PCR template corresponding approximately
to 2–3 ng of DNA, and sufficient distilled water forAnnealing T° (time) Expected size Reference
66°C (1 min) 210 bp [21]
64°C (1 min) 248 bp [21]
55°C (45 sec) 207 pb [18]
65°C (1 min) 237 bp [21]
62°C (30 sec) 158 bp [21]
62°C (1 min) 238 bp [12]
62°C (1 min) 240 bp [12]
58°C (30 sec) 375 bp [12]
65°C (45 sec) 334 bp [22]
65°C (45 sec) 338 bp [17]
65°C (45 sec) 368 bp [23]
62°C (1 min) 886 pb -
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tors were removed by treatment on a sephadex column.
The obtained sequences were aligned using the assembling
application of vector NTI (Invitrogen) and CodonCode
Aligner, and polymorphisms detection was achieved by
comparison with the published M. tuberculosis H37Rv
sequence.
Quality control
M. tuberculosis H37Rv (ATCC 27294) was included as a
quality controls for the phenotypic and genotypic tests.
Results
Analysis of INH -resistance associated mutation
A total of 44 INHR (24 high level and 20 low level)) and
100 matched INHS sensitive control strains were screened
for mutations at katG codon 315, the fabG1-inhA regula-
tory region, the inhA ORF, the oxyR-ahpC intergenic region
by DNA sequence analysis. A complete list of specific mu-
tations, which had been identified is provided in Table 2.
Polymorphisms in the katG gene
Among the 24 high level INH-resistant isolates, 18 (75%)
were genetically altered in the katG region. Out of these,
17 (70.8%) had a resistance associated mutation in katG
codon 315 and one isolate had a partial katG gene deletion
(Table 2).
Of the 18 isolates altered in the katG gene, 7 had an
additional mutation in the fabG1-inhA regulatory region
(2 at position −15C→ T and 5 at position −47G→C).
The katG315 mutations resulted in a change of the wild-
type codon, AGC (Ser) to ACC (Thr) in 17 strains and
AAC (Asn) in one strain. All of the INH susceptible
strains lacked mutations in katG 315. Thus for detection
of high level INH -resistance, mutation/partial deletionTable 2 Isoniazid resistance- associated mutations detected in
Gene N° of isolates
tested









fabG1-inhA regulatory region 44 INHR 13 −
5 −4
26
100 INHS 24 −4
3 −1
NA = not applicable; WT = wild type; INHR = isoniazid resistant isolate; INHS = isoniazof the katG gene had a specificity of 100.0% and a sensi-
tivity of 75% (18/44).
Of the 20 low level INH-resistant isolates, 2 (10%)
harboured the katG315 mutation. In total, the katG315
mutation was seen in 19 isolates with 16 (84.2%) being
high level INH-resistant isolates. Therefore, this muta-
tion might be associated with high level INH -resistance
(1 μg/ml). Overall, for the detection of INH -resistance,
mutation/partial deletion of the katG gene had a specifi-
city of 100.0% and a sensitivity of 45.5% (20/44).
Polymorphisms in the inhA gene
The inhA region consists of two genes, fabG1 and inhA.
Among the 24 high level INH-resistant isolates, 3 har-
boured the mutation −15C→ T in the regulatory region
of inhA with 2 of them carrying an additional katG315
mutation and 5 had nucleotide changes (G→C) at pos-
ition −47. All the 5 INH-resistant isolates with −47 G→C
mutation also harbored the katG315 mutation.
Out of the 20 low level INH-resistant isolates, 10 (50%)
had mutations in fabG1-inhA leading to a C→T change at
position −15 of the start site of fabG. In total, the fabG1-
inhA mutation at −15 position was observed in 13 isolates
with 10 (77%) being low level INH-resistant isolates.
Therefore, this mutation seems to be associated with low
level INH -resistance (0.2 μg/ml). None of the INH suscep-
tible isolates had the mutation affecting the inhA promoter
region at position −15. On the contrary, the nucleotide
change at position −47 was also seen in 24 isoniazid sus-
ceptible isolates and a new mutation −102C→T not yet
described was detected in 3 other INH susceptible isolates.
No mutation was observed in inhA ORF gene (Table 3).
Polymorphisms in the oxyR-ahpC intergenic region
One low level INH-resistant isolate displayed a G→A





N° of mutated isolates according
to INH resistance level
Low level (0.2 μg/ml) High level (1 μg/ml)
GC→ ACC Ser→ Thr 2 16
GC→ AAC Ser→ Asn 0 1
al deletion NA 0 1
WT NA 0 0
WT NA NA NA
15C→ T NA 10 3
7G→ C NA 0 5
WT NA 0 0
7G→ C NA NA NA
02C→ T NA NA NA
id sensitive isolate; N°: number.
Table 3 Rifampicin resistance-associated mutations
detected in M. tuberculosis study isolates










rpoB 7 RIFR 5 531TCG→ TTG Ser→ Leu
1 526CAC→ GAC His→ Asp
1 516GAC→ GTC Asp→ Val
100 RIFS 1 516GAC→ TAC Asp→ Tyr
NA = not applicable; WT = wild type; RIFR = rifampicin resistant isolate;
RIFS = rifampicin sensitive isolate, N° = Number.
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which has previously been shown to be involved in
INH -resistance [15].
Combined sensitivity and specificity of katG and inhA
promoter region for INH resistance
Mutations in katG315 and −15C→T in inhA promoter re-
gion accounted together for 73% (33/44) INH -resistance.
Since none of these mutations was observed in susceptible
isolates, the combined specificity is 100%.
Analysis of the rpoB gene responsible for RIF-resistance
In this study, 7 RIFR isolates, and 100 RIF-sensitive (RIFs)
clinical isolates were examined for mutations in a 158-bp
fragment of rpoB gene. Of 7 RIFR isolates, resistance-
associated mutations in the core region of rpoB were
found in all 7 (100.0%) isolates (Table 3). The nucleotide
and amino acid changes identified in drug-resistantTable 4 Streptomycin and ethambutol resistance-associated m
Resistance to Gene N° and type of isolates tested N° of isolates w








embB 2 EMBR 100 EMBS
*: synonymous mutation; NA = not applicable; WT = wild type; SMR = streptomycin r
resistant isolate; EMBS = ethambutol sensitive isolate; N° = Number.isolates are shown in Table 4. Three different rpoB mu-
tations were identified involving codons 516, 526, and
531. The most common mutation, which changes TCG
(Ser) to TTG (Leu) in codon 531, was detected in 5
(71.4%) of the 7 mutated RIF-resistant isolates (Table 3).
A mutation affecting codon 516 and leading to a substi-
tution of aspartate to tyrosine was observed in the rpoB
gene of one RIF sensitive isolate. Hence, mutations in
the rpoB gene exhibited a sensitivity of 100.0% and a
specificity of 99.0%.
Analysis of mutations in the target regions of
SM -resistance
All strains were first sequenced (27 SMR isolates and 100
fully susceptible isolates) in the rrs gene. As none of the
resistant strains displayed a mutation in this gene, se-
quence analysis of rpsL was performed. Among the 27
SMR strains 2 carried a mutation in rpsL gene at codon 43
and none showed a polymorphism at codon 88. The 2 re-
sistant isolates mutated at codon 43 had a Lys→Arg sub-
stitution (Table 4). The remainder of the phenotypically
resistant strains (n = 25) did not carry a mutation in rpsL
gene and no changes were found in the drug-susceptible
isolates. The specificity of rpsL43 mutation for resistance
detection of SMR was 100%.
Additionally all strains were sequenced in gidB gene. In
this very polymorphic gene, 5 different mutations with 3
of them never been reported were found in 5 SMR strains
and 2 different mutations in 6 SMS strains (see Table 4).
The 5 mutations at codon 36GTG→GGG, 48CAT→utations detected in M. tuberculosis study isolates
ith indicated genotype Nucleotide change Amino acid change
2 43AAG→ AGG Lys→ Arg
0 WT NA
1 138GCG→ CCG Ala→ Pro
1 79TTG→ TGG Leu→ Trp
1 75CCG→ TCG Pro→ Ser
1 48CAT→ AAT His→ Asn
1 36GTG→ GGG Val→ Gly
3 205GCA→ GCG Ala→ Ala*
3 16CTT→ CGT Leu→ Arg
0 WT NA
3 −20A→ C NA
3 −230A→ C NA
0 WT NA
3 330CTG→ TTG Leu→ Leu*
1 306 Met→ Val
0 WT NA
esistant isolate; SMS = streptomycin sensitive isolate; EMBR = ethambutol
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were exclusively found in streptomycin resistant strains
while the mutations at codon 205GCA→GCG and
16CTT→CGT were exclusively found in streptomycin
sensitive strains.
Analysis of mutations in the target regions of
EMB -resistance
In this study, we analyzed polymorphisms in the embCAB
operon for 2 ethambutol resistant isolates and 100 eth-
ambutol sensitive isolates. Among our 2 EMB -resistant
isolates, sequence analysis of the embB gene identified 1
isolate with EMB-resistance-associated nucleotide substi-
tutions in codon 306ATG→GTG that result in amino
acid replacement (306Met→ Val) and the remaining
isolate as well as all sensitive isolates had no amino acid
replacements in embB gene. As embB mutations are not
the only ones involved in EMB-resistance mechanisms
in M. tuberculosis, we also analyzed embC and embA
loci for mutations. Sequence analyses of embC and
embA revealed no mutations in EMB -resistant isolates
while 6 of 100 fully susceptible isolates have mutations
at position −20A→C and −230A→C of embC upstream
region. Although the substitutions at position −20A→C
were present only in EMB-susceptible organisms in our
sample, these three strains also had synonymous muta-
tion at codon 330CTG→ TTG of the embA gene and
nucleotides replacement at position -102C→ T in the
regulatory region of fabG1-inhA operon; this is exclu-
sively found in susceptible organisms. The 3 samples
with mutations at position −230A→ C also harbored
simultaneously a nucleotide replacement at position −47
in the regulatory region of fabG1-inhA operon. Three of
100 fully susceptible strains had synonymous mutations
at codon 330CTG→ TTG of embA gene, which did not
resulting in amino acid replacement. These 3 isolates
harbored simultaneously nucleotide replacement at
position −20 upstream of the initiation site of embC gene.
All EMB susceptible strains (n = 100) had a wild-type
embB sequence.
Discussion
Early detection of drug resistance constitutes one of the
priorities of TB control programs. It allows initiation of
the appropriate treatment in patients and avoids dissemin-
ation of resistant strains in the community. In the context
of a poor resource country, detection of drug resistance
is performed in the reference laboratory by so-called
‘conventional methods’ based on detection of growth of
M. tuberculosis in the presence of the respective antibi-
otics. Depending on the method, this process requires
at least 10 days to 8 weeks before drug sensitivity results
are available. During this time the infected patient may
be treated incorrectly which may have serious healthimplications in particular in patients with HIV-TB coin-
fection. The disclosure of the genetic basis of resistance
to anti-tuberculous agents has enabled development of
new molecular tests to detect mutations associated with
reduced susceptibility to antituberculous drugs [9,10].
In order to detect and validate the drug resistance asso-
ciated mutations, DNA sequencing is the most accurate
among the molecular techniques. We used PCR fragment
sequencing since molecular mechanisms explaining resist-
ance to anti-tuberculous agents are not fully understood
[24]. It presents the advantage, over methods that use
DNA probes, to detect unknown mutations. Recently the
GeneXpert has been endorsed by the WHO for point of
care testing [25]. Drug sensitivity testing with this method
is based on the detection of mutations in the core region
of the rpoB gene, thus only RIF-resistance or MDR would
be detected.
In this study, we set out to investigate the association
of phenotypic resistance with genetic mutations in drug
resistance TB isolates in Cameroon. The majority of the
isolates in this study were from the Jamot Hospital
(Central Region of Cameroon), the reference hospital
for diagnostic and treatment of pulmonary diseases
throughout the country. Therefore, the data obtained in
this study can be considered to be representative of the
make-up of resistance conferring mutations present in
M. tuberculosis strains in this region.
A 158-bp fragment of the rpoB gene from codon 507
to 533 was amplified and sequenced to detect mutations
in RIFR strains. Of the 7 phentotypically RIFR strains, mu-
tations were found in the rifampicin resistant determining
region (RRDR) for all the 7 isolates. These alterations af-
fected the codons Ser531Thr (71.4%), His526Asp (14.3%)
and Asp516Val (14.3%). The rpoB codons 531, 526, and
516 are the most frequently mutated codons worldwide,
although variations in the relative frequencies of muta-
tions in these codons have been described for M. tubercu-
losis isolates from different geographic locations. The
most common site of nucleotide substitutions in RIFR
isolates was codon 531. This finding was similar to those
reported in Russia [26], the US [27], Tunisia [28] Ghana
[21] and Germany [29]. The codon 531 mutation was also
reported as the most frequent (68%) in M. tuberculosis
isolates of the LAM family in Cameroon [30]. For co-
dons 526 and 516 involved in RIFR, mutations in our
strains occurred at equal frequencies than in strains
from other geographical regions [31-33]. It has been
shown that various substitutions in the same codon can
lead to different level of resistance. Mutations at codon
516 of the rpoB gene can confer either low or high level
resistance depending on the codon change [34]. It has
been reported that substitution of aspartate by tyrosine
in codon 516 induced RIF-resistance of M. tuberculosis
with minimum inhibitory concentration (MIC) between
Tekwu et al. BMC Microbiology 2014, 14:113 Page 7 of 10
http://www.biomedcentral.com/1471-2180/14/11315 μg/ml and 25 μg/ml in BACTEC 460-TB system [34]. In
our study, RIF susceptibility was evaluated in Lowenstein
Jensen at a concentration of 50 μg/ml. This might explain
why strains harbouring this mutation in our study were
phenotypically RIF-susceptible. Among the 7 isolates
which were altered genetically, 6 were MDR strains and
one a RIF-SM-resistant isolate. Thus, rpoB could be an in-
dicator of multidrug resistance among M. tuberculosis
strains. This observation was previously reported among
Cameroonian M. tuberculosis isolates [30].
It has been previously shown that about 10–15.9% of
RIF -resistant isolates do not have mutations in the
RRDR [15]. More than 90% of RIF -resistant strains
from other regions had mutations located in the 81-bp
core region [35-38]. This indicated a possible occur-
rence of alteration outside the core region of 81 bp of
the examined rpoB. Among other explanations, several
additional genes might be involved in RIF-resistance
such as rpoA, rpoC or rpoD [39]. The natural resistance
to RIF in some M. avium and M. intracellular strains is
known to be a result of efficient cell wall permeability
and exclusion barrier, suggesting that these elements
could also play an important role in M. tuberculosis
[34]. However, in our study, all the isolates harboured
mutations in the RRDR core region.
Common genes known to be involved in INH-resistance
are katG, inhA, ahpC, oxyR [10]. Several investigators have
shown that INH-resistance in M. tuberculosis isolates arise
principally from a katG gene alteration [40-42] that corre-
sponds essentially to point mutations in codon 315 (point
mutations in two bases 944 and 945). In this study, 18
(40.0%) INH -resistant isolates were genetically altered in
the katG codon 315. Others studies have reported 95% of
all INH-resistant isolates with mutations in codon 315
[43]. Out of the 6 MDR strains identified in this study, 5
displayed a high level resistance to isoniazid with a katG
alteration and the remaining one displayed a low level
INH-resistance with −32G→A mutation in oxyR-ahpC
intergenic region. Therefore, it will be useful to combine
katG315 and −15 point mutation inhA promoter region
with rpoB in molecular assays looking at drug resistance.
Since some of the INHR strains in this study had no muta-
tion in katG315 and −15 inhA promoter region, it is likely
that mutations in other genes, such as the inhA locus,
contribute to resistance. Previous studies have shown that
mutations in the upstream region of the inhA locus result
in increased levels of InhA (NADH-dependent enoyl-acyl
carrier protein reductase) expression, thereby elevating the
drug target levels and producing INH -resistance via a ti-
tration mechanism [15]. We assessed for mutations in the
inhA regulatory region of all the 44 INHR M. tuberculosis
strains and found a substitution at position 15 upstream
of the start codon in 13 (28.9%) isolates. The frequency
of the occurrence of specific INH-resistance conferringmutations varied between geographical regions in the
world [26]. A study in Equatorial Guinea reported the
absence of mutation in the katG gene of M. tuberculosis
INH -resistant isolates [44]. The unique katG mutation
observed in this study was the substitution of Serine to
Threonine at codon 315. High proportion of Ser315katG
mutations has been reported in Russia (76.9%) [26], in
Morocco (68.6%) [45], in isolates of the LAM family in
Cameroon [30] and also in Korea (49.1%) [46]. In INHR
strains, neither insertions nor complete deletions of katG
were found, which is evidence of the rare occurrence of
these mutations in clinical isolates, although they were
reported previously by other authors [47,48]. Fourteen
(31.8%) INHR isolates did not show mutations at the
four loci analyzed. This discrepancy between the pheno-
typic results and the genotypic drug resistance tests
could be attributed to the presence of other mutations
located either outside the selected target region or the
selected genes. Several others studies have reported that
mutations in inhA or its promoter region are usually as-
sociated with low-level resistance of INH. Moreover,
INH-resistant isolates with inhA mutations can have
additional mutations in katG, conferring higher levels of
INH-resistance [11].
All mutations found in fabG1-inhA promoter region
were not associated with phenotypic resistance. The sub-
stitution of G to C at position −47 first described by
Homolka and al. [21] in an INH-resistant strain has been
found in both susceptible (24/44; 54.5%) and resistant iso-
lates (5/44; 11.4%). Thus, this mutation seems to not cor-
relate with INH-resistance. The mutation −102 C→T not
yet described is also not relevant to INH-resistance since
it was found only in susceptible isolates.
The analysis of SM-resistance mechanism revealed
that none of the SM-resistant strains carried a mutation
in the rrs gene although those mutations have been de-
scribed as main resistance mechanism that confer high
level SM -resistance [12]. Clinical isolates showing no
mutations in rpsL or rrs gene have been reported in the
literature [49]. A previous investigation from Cameroon
encountered rpsL or rrs mutations in SM-resistant iso-
lates from the Central Region of Cameroon [50]. In con-
trast in the current investigation only rpsL mutations
were associated with SM-resistance. This indicates that
further studies are necessary to delineate the molecular
markers for SM-resistance. Mutations in the rpsL locus
have been hypothesized to be an alternative mechan-
ism of SM-resistance like mutations in the gidB [51] or
efflux pumps [13]. Overall, we detected gidB mutations
in 18.5% of SM-resistant isolates and 6% of SM suscep-
tible isolates. Although the encountered mutations in
resistant samples were not observed in susceptible iso-
lates, their association with SM-resistance needs to be
confirmed.
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http://www.biomedcentral.com/1471-2180/14/113Three contiguous genes encoding arabinosyl transferases
and designated embC, embA, and embB were analyzed in
the present study. These 3 genes have been identified in
M. tuberculosis [52]. Previous studies based on limited se-
quencing region containing the embCAB genes have iden-
tified mutations that result in replacement of amino acid
residues and are found only in EMB-resistant organisms
cultured from humans [52]. In this study, the embB ana-
lysis gene identified 1 of 2 resistant isolates with EMB-
resistance-associated nucleotide substitutions in codon
306ATG→GTG that result in amino acid replacement
(Met→Val). This is in accordance with others studies
analyzing EMB-resistant clinical isolates of M. tuberculosis
that identified embB amino acid-conferring mutations
in approximately 50 to 70% isolates with resistance-
associated polymorphisms [52]. Certain variations af-
fecting embA (330CTG→ TTG) and embC (−20A→ C
and −230 A→ C) appeared to be not associated with
drug resistance. Given the low number of EMB-resistant
isolates in our investigation further studies are needed to
confirm these findings.Conclusion
This study provided the first molecular characterization
of M. tuberculosis drug resistance in the Central Region
of Cameroon using DNA sequencing. rpoB and katG315
mutations known to be involved in resistance had high
specificities and sensitivities for detecting RIF- and INH-
resistance respectively. However, the correlation between
molecular and phenotypic resistance testing for the de-
termination of SM- and EMB-resistance was lower. This
study clearly shows the need for continuous phenotypic
and genotypic characterization of drug resistance at the
national level in order to determine the most suitable
molecular marker for drug resistance in our setting. The
fact that mutations at codon katG315 and at the rpoB
gene show high specificities for resistance against INH
or RIF respectively suggests that these may be suitable
molecular marker for diagnostic test in Cameroon. Con-
sequently the WHO recommended GeneXpert technol-
ogy is appropriate for the detection RIF-resistance in the
Central Region of Cameroon.Abbreviations
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